文献速递免疫规划慢病防控与筛查

甲氨蝶呤降低类风湿关节炎患者接种肺炎球菌结合疫苗后的疫苗特异性免疫球蛋白水平但不减少循环产抗体B细胞数量

Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
PubMed 文献 · Vaccine · 2017-01-09

研究纳入10例使用甲氨蝶呤的类风湿关节炎患者和10例未使用改善病情抗风湿药的患者,接种13价肺炎球菌结合疫苗。甲氨蝶呤组疫苗特异性抗体应答及调理功能低于未用药组,但循环总IgG/IgA及疫苗特异性IgG/IgA浆母细胞数量两组无差异。

要点

  • 甲氨蝶呤组仅对血清型6B抗体水平较接种前显著升高(p<0.05),未用药组对6B和23F均显著升高(分别为p<0.05和p<0.01)。
  • 两个血清型均出现阳性抗体应答者:甲氨蝶呤组10%,未用药组40%。
  • 接种后调理能力增强者:甲氨蝶呤组4例中1例,未用药组4例中3例;循环浆母细胞数量两组无差异。

核心结论

  • 类风湿关节炎患者使用甲氨蝶呤后接种多糖-蛋白结合肺炎球菌疫苗,疫苗特异性抗体应答及功能较未治疗患者降低。
  • 由于循环总IgG/IgA及疫苗特异性IgG/IgA浆母细胞数量未减少,该效应可能并非源于淋巴组织中B细胞活化减少。

研究设计与样本

  • 研究纳入10例使用甲氨蝶呤的类风湿关节炎患者和10例未使用改善病情抗风湿药的类风湿关节炎患者,接种13价肺炎球菌结合疫苗(Prevenar13)。
  • 接种后6天用ELISPOT计数产生总IgG和IgA及针对肺炎球菌荚膜血清型6B和23F特异性IgG和IgA的循环浆母细胞。
  • 接种前及接种后4-6周用ELISA测定针对6B和23F的IgG水平;阳性抗体应答定义为较接种前抗体水平升高≥2倍。
  • 在随机选择的4例使用甲氨蝶呤和4例未使用改善病情抗风湿药的患者中,用调理吞噬试验评估针对血清型23F疫苗特异性抗体的调理能力。
  • 临床试验注册号:NCT02240888。

主要发现

  • 接种后,甲氨蝶呤组对6B的抗体水平较接种前显著升高(p<0.05),未用药组对6B和23F均显著升高(分别为p<0.05和p<0.01)。
  • 两个血清型均出现阳性抗体应答者:甲氨蝶呤组10%,未用药组40%。
  • 接种后调理能力增强者:甲氨蝶呤组4例中1例,未用药组4例中3例。
  • 循环总IgG/IgA及疫苗特异性IgG/IgA浆母细胞数量在是否使用甲氨蝶呤的类风湿关节炎患者间无差异。

关键数值与推荐

  • 阳性抗体应答定义为接种后抗体水平较接种前升高≥2倍。
  • 甲氨蝶呤组两个血清型均阳性应答者10%,未用药组40%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment with methotrexate (MTX) in patients with rheumatoid arthritis (RA) leads to decreased total immunoglobulin (Ig) levels and impairs vaccine-specific IgG antibody levels following pneumococcal vaccination. The mechanisms by which MTX exerts these effects in RA are unknown. We aimed to evaluate whether MTX reduces vaccine-specific serum Ig levels and their functionality in RA patients following vaccination with pneumococcal conjugate vaccine, and if numbers of antigen-specific circulating plasmablasts are affected. METHODS: Ten patients with RA on MTX and 10 RA patients without disease modifying anti-rheumatic drug (DMARD) were immunized with a dose 13-valent pneumococcal conjugate vaccine (Prevenar13). Circulating plasmablasts producing total IgG and IgA as well as specific IgG and IgA against two pneumococcal capsular serotypes (6B and 23F) were enumerated using ELISPOT 6days after vaccination. IgG levels against both these serotypes were determined with ELISA before and 4-6weeks after vaccination. Positive antibody response was defined as ⩾2-fold increase of pre-vaccination antibody levels. The functionality of vaccine specific antibodies to serotype 23F was evaluated by measuring their ability to opsonize bacteria using opsonophagocytic assay (OPA) in 4 randomly chosen RA patients on MTX and 4 RA patients without DMARD. RESULTS: After vaccination, RA patients on MTX showed significant increase in pre- to postvaccination antibody levels for 6B (p<0.05), while patients without DMARD had significant increases for both 6B and 23F (p<0.05 and p<0.01, respectively). Only 10% of RA on MTX and 40% of RA patients without DMARD showed positive post-vaccination antibody responses for both serotypes. Increased opsonizing ability after vaccination was detected in 1 of 4 RA patients on MTX and 3 of 4 patients on RA without DMARD. However, numbers of circulating total and vaccine-specific IgG- or IgA-producing plasmablasts did not differ between RA patients with or without MTX. CONCLUSIONS: MTX treatment in RA leads to reduced vaccine-specific antibody responses and their functionality compared to untreated RA following pneumococcal vaccination using polysaccharide-protein conjugate vaccine. However, since there was no reduction in numbers of circulating total or vaccine-specific antibody-producing plasmablasts after vaccination this effect is probably not due to reduced activation of B cells in lymphoid tissue. CLINICAL TRIAL REGISTRATION: NCT02240888.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kapetanovic MC, Nagel J, Nordström I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017. PMID: 28081972. doi:10.1016/j.vaccine.2016.12.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。